Oral ciprofloxacin as prophylaxis in transurethral resection of the prostate.

A new quinolone antibacterial, ciprofloxacin, was evaluated as oral prophylaxis for transurethral resection of the prostate in a randomised controlled trial. A 3-day course of perioperative ciprofloxacin 250 mg twice daily reduced the post-operative infection rate, the post-operative hospital stay and the frequency of infective complications. Ciprofloxacin was well tolerated and no significant haematological or biochemical side effects were detected.

RCT Entities:   Population Interventions Outcomes